Development of Digital Biomarkers in Multiple Sclerosis: Validation Study 2

Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Mar 6, 2024

Keywords

ClinConnect Summary

This clinical trial, called "Development of Digital Biomarkers in Multiple Sclerosis: Validation Study 2," is focused on improving how we monitor and treat multiple sclerosis (MS), a long-term disease that affects the brain and spinal cord. Researchers are exploring new digital tools that can help track a patient’s health status and disease progression more accurately and continuously, without needing frequent visits to the clinic. The goal is to use these digital biomarkers to enhance the traditional methods of assessment, making treatment more personalized and effective for each individual.

To participate in this study, you need to be at least 18 years old and diagnosed with MS, which can include different types of the disease. Participants should have a smartphone that works with the Healios+Me app, and they should be able to see and use the phone comfortably. This trial is not yet recruiting, but once it begins, participants can expect to use their smartphones to help researchers gather valuable information about their condition. This study also aims to create a framework for future research, promoting collaboration across different countries and cultures.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18
• • Diagnosed with MS according to the revised McDonald criteria 2017, all clinical forms inclusive (CIS, RRMS, SPMS, PPMS)
• • In possession of a Healios+Me app-compatible smartphone (iOS/Android)
• • Corrected close visual acuity of ≥0.5
• • Hand motor skills sufficient for using a smartphone
• • Ability and intention to follow the study procedures
• • Sufficient knowledge of the language for the specific country
• • Informed Consent as documented by signature
• Exclusion Criteria:
• • NA